Najafov Ayaz, Chen Hongbo, Yuan Junying
Department of Cell Biology, Harvard Medical School, 240 Longwood Ave. Boston, MA 02115.
Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Trends Cancer. 2017 Apr;3(4):294-301. doi: 10.1016/j.trecan.2017.03.002.
Necroptosis is a programmed lytic cell death pathway, deregulation of which is linked to various inflammatory disorders. Escape from programmed cell death and inflammation play a significant role in cancer, and therefore, investigating the role of necroptosis in cancer has been of high interest. Necroptosis has been shown to promote cancer metastasis and T cells death. Escape from necroptosis via loss of RIPK3 expression is a feature of some cancers. While necroptosis is a promising novel target for cancer therapies, further investigation into its biological role in carcinogenesis is warranted. In this article, we review the recently-identified interplay points between necroptosis and cancer, and outline major biological questions that require further inquiry on the road to targeting this pathway in cancer.
坏死性凋亡是一种程序性溶解性细胞死亡途径，其失调与多种炎症性疾病相关。逃避程序性细胞死亡和炎症在癌症中起着重要作用，因此，研究坏死性凋亡在癌症中的作用一直备受关注。已表明坏死性凋亡可促进癌症转移和T细胞死亡。通过RIPK3表达缺失逃避坏死性凋亡是某些癌症的一个特征。虽然坏死性凋亡是癌症治疗的一个有前景的新靶点，但有必要进一步研究其在致癌过程中的生物学作用。在本文中，我们综述了最近发现的坏死性凋亡与癌症之间的相互作用点，并概述了在将该途径作为癌症治疗靶点的道路上需要进一步探究的主要生物学问题。
